Kura Oncology, Inc. (NASDAQ:KURA) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Wall Street analysts rate Kura Oncology “Moderate Buy”: 11 of 13 analysts recommend buying, while one rates it hold and one sell. The average one-year price target is $25.35.
• Kura shares opened at $7.61, near their 52-week low of $7.36; the stock’s 52-week high is $13.90.
• The company beat quarterly estimates, reporting a loss of $0.77 per share versus the expected $0.88 loss, and revenue of $20.87 million versus $20.16 million expected. CEO Troy Wilson also bought 100,000 shares for about $1.11 million.

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $25.35.

A number of brokerages have recently commented on KURA. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a research report on Wednesday, October 14th. Morgan Stanley set a $24.00 price target on Kura Oncology in a report on Monday, August 24th. Deutsche Bank Aktiengesellschaft set a $24.00 price objective on Kura Oncology in a research note on Wednesday, October 14th. Citigroup restated a "market outperform" rating on shares of Kura Oncology in a report on Wednesday, October 14th. Finally, JPMorgan Chase & Co. assumed coverage on Kura Oncology in a report on Thursday, October 1st. They set an "overweight" rating and a $30.00 price objective on the stock.

Kura Oncology Price Performance

KURA stock opened at $7.61 on Thursday. Kura Oncology has a 52 week low of $7.36 and a 52 week high of $13.90. The firm has a market capitalization of $676.99 million, a P/E ratio of -2.26 and a beta of 0.56. The company has a fifty day simple moving average of $10.94 and a two-hundred day simple moving average of $9.81. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.11. The firm had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. Analysts anticipate that Kura Oncology will post -3.25 earnings per share for the current fiscal year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, CEO Troy Wilson bought 100,000 shares of Kura Oncology stock in a transaction that occurred on Monday, August 17th. The shares were bought at an average cost of $11.12 per share, with a total value of $1,112,000.00. Following the transaction, the chief executive officer directly owned 379,194 shares of the company's stock, valued at approximately $4,216,637.28. This represents a 35.82% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Teresa Bair sold 31,487 shares of Kura Oncology stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $12.63, for a total transaction of $397,680.81. Following the completion of the sale, the insider owned 195,444 shares of the company's stock, valued at $2,468,457.72. This trade represents a 13.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 153,881 shares of company stock worth $1,708,183. Company insiders own 7.60% of the company's stock.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. IFP Advisors Inc increased its holdings in Kura Oncology by 136.5% during the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company's stock worth $28,000 after purchasing an additional 1,467 shares during the period. Sterling Capital Management LLC grew its position in shares of Kura Oncology by 842.5% in the 3rd quarter. Sterling Capital Management LLC now owns 2,818 shares of the company's stock valued at $30,000 after buying an additional 2,519 shares during the last quarter. Physician Wealth Advisors Inc. purchased a new position in shares of Kura Oncology during the third quarter worth about $43,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Kura Oncology during the third quarter worth approximately $49,000. Finally, Pictet Asset Management Holding SA purchased a new position in Kura Oncology during the 1st quarter worth $96,000.

Kura Oncology Company Profile

Kura Oncology, Inc NASDAQ: KURA is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company's research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.

Kura's lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.